CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
ABT199drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02677324
NCT02677324Phase 2Completed
CompareCT.gov

Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Dana-Farber Cancer Institute·interventional·Posted Feb 9, 2016·Updated May 11, 2022

In Brief

A Phase 2 clinical trial evaluating ABT199 for Waldenstrom Macroglobulinemia. Completed, enrolled 33 participants across 4 sites.

Detailed Summary

This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom Macroglobulinemia
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 9, 2016
Enrollment StartMay 9, 2016
Primary CompletionFeb 14, 2020
Study CompletionFeb 7, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.4 years ago

Interventions

ABT199drug

Oral BCL-2 antagonist